Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 1, 2014, Pages 214-223

  Varma, Manthena V ^a   Bi, Yi An ^a   Kimoto, Emi ^a   Lin, Jian ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BOSENTAN; CERIVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450; FLUINDOSTATIN; GEMFIBROZIL; GLIBENCLAMIDE; ITRACONAZOLE; PITAVASTATIN; PRAVASTATIN; REPAGLINIDE; RIFAMPICIN; ROSUVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; VALSARTAN; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ORGANIC ANION TRANSPORTER;

ARTICLE; BILE SECRETION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; ENZYME INHIBITION; ENZYME METABOLISM; EXTENDED NET EFFECT MODEL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MATHEMATICAL MODEL; PREDICTION; PROTEIN METABOLISM; BIOLOGICAL MODEL; CELL CULTURE; DRUG EFFECTS; DRUG INTERACTION; LIVER CELL; METABOLISM;

ANTI-INFECTIVE AGENTS; ANTIHYPERTENSIVE AGENTS; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HEPATOCYTES; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MODELS, BIOLOGICAL; ORGANIC ANION TRANSPORTERS;

EID: 84907180162     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.215970     Document Type: Article

References (52)

1. Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, Lin J, and Varma MV (2013) Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opin Drug Metab Toxicol 9:459-472.
2. Benet LZ, Broccatelli F, and Oprea TI (2011) BDDCS applied to over 900 drugs. AAPS J 13:519-547.
3. Bi YA, Kazolias D, and Duignan DB (2006) Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos 34: 1658-1665.
4. Bi YA, Qiu X, Rotter CJ, Kimoto E, Piotrowski M, Varma MV, Ei-Kattan AF, and Lai Y (2013) Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin. Biopharm Drug Dispos 34:452-461.
5. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, and Ni L, et al.; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER) (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832.
6. Camenisch G and Umehara K (2012) Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions. Biopharm Drug Dispos 33:179-194.
7. Darwich AS, Neuhoff S, Jamei M, and Rostami-Hodjegan A (2010) Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr Drug Metab 11:716-729.
8. Einolf HJ, Chen L, Fahmi OA, Gibson CR, Obach RS, Shebley M, Silva J, Sinz MW, Unadkat JD, and Zhang L, et al. (2014) Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clin Pharmacol Ther 95:179-188.
9. European Medicines Agency (2012) Guideline on the Investigation of Drug Interactions. Committee for Human Medicinal Products, London.
10. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, and Nettleton D (2008) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698-1708.
11. Fan J, Chen S, Chow EC, and Pang KS (2010) PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr Drug Metab 11:743-761.
12. Feng B, Hurst S, Lu Y, Varma MV, Rotter CJ, El-Kattan A, Lockwood P, and Corrigan B (2013) Quantitative prediction of renal transporter-mediated clinical drug-drug interactions. Mol Pharm 10:4207-4215.
13. Fenner KS, Jones HM, Ullah M, Kempshall S, Dickins M, Lai Y, Morgan P, and Barton HA (2012) The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. Xenobiotica 42:28-45.
14. Gertz M, Cartwright CM, Hobbs MJ, Kenworthy KE, Rowland M, Houston JB, and Galetin A (2013) Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential. Pharm Res 30:761-780.
15. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9: 215-236.
16. Gui C, Miao Y, Thompson L, Wahlgren B, Mock M, Stieger B, and Hagenbuch B (2008) Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 584:57-65.
17. Hinton LK, Galetin A, and Houston JB (2008) Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm Res 25:1063-1074.
18. Ieiri I, Higuchi S, and Sugiyama Y (2009) Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for interindividual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5:703-729.
19. Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, and Rowland-Yeo K (2014) A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet 53:73-87.
20. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, and Galetin A, et al. (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007-1017.
21. Kalliokoski A and Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705.
22. Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, Nagata Y, Takakuwa S, Tsukamoto Y, and Ueda K, et al. (2003) The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 18:365-372.
23. Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, El-Kattan A, Sugiyama Y, and Lai Y (2012) Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm 9:3535-3542.
24. Kitamura S, Maeda K, Wang Y, and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36: 2014-2023.
25. Lai XS, Yang LP, Li XT, Liu JP, Zhou ZW, and Zhou SF (2009) Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr Drug Metab 10:1009-1047.
26. Lai Y, Varma M, Feng B, Stephens JC, Kimoto E, El-Kattan A, Ichikawa K, Kikkawa H, Ono C, and Suzuki A, et al. (2012) Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability: considerations for drug development. Expert Opin Drug Metab Toxicol 8:723-743.
27. Li R, Barton HA, and Varma MV (2014) Prediction of pharmacokinetics and drugdrug interactions when hepatic transporters are involved. Clin Pharmacokinet 53: 659-678.
28. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R, and Collins R; SEARCH Collaborative Group (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359:789-799.
29. Liu L and Pang KS (2005) The roles of transporters and enzymes in hepatic drug processing. Drug Metab Dispos 33:1-9.
30. Lundquist P, Lööf J, Sohlenius-Sternbeck AK, Floby E, Johansson J, Bylund J, Hoogstraate J, Afzelius L, and Andersson TB (2014) The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions. Drug Metab Dispos 42:469-480.
31. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, Yamane N, Kumagai Y, and Sugiyama Y (2011) Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90:575-581.
32. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, and Sundaresen P (2000) Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 68:391-400.
33. Ménochet K, Kenworthy KE, Houston JB, and Galetin A (2012) Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab Dispos 40:1744-1756.
34. Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, and Kivistö KT (2005) Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype ∗17. Pharmacogenet Genomics 15:303-309.
35. Niemi M, Pasanen MK, and Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-181.
36. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, and Urasaki Y, et al. (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554-565.
37. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
38. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
39. Pang KS and Rowland M (1977) Hepatic clearance of drugs. II. Experimental evidence for acceptance of the "well-stirred" model over the "parallel tube" model using lidocaine in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm 5:655-680.
40. Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, Dempsey C, Rasmussen S, Houle R, and Chan G, et al. (2014) Pitavastatin is a more sensitive and selective OATP1B clinical probe than rosuvastatin. Br J Clin Pharmacol DOI: 10.1111/bcp.12377 [published ahead of print].
41. Shitara Y, Horie T, and Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-446.
42. Shitara Y and Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71-105.
43. Tomita Y, Maeda K, and Sugiyama Y (2013) Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Clin Pharmacol Ther 94:37-51.
44. US FDA (2012) Drug Interaction Studies: Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Center for Drug Evaluation and Research, Silver Spring, MD.
45. van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, and Dingemanse J (2007) Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther 81:414-419.
46. Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, and Bergman A (2012) Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res 29:2860-2873.
47. Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, and Kumar V (2013a) Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res 30:1188-1199.
48. Varma MV, Lin J, Bi YA, Rotter CJ, Fahmi OA, Lam JL, El-Kattan AF, Goosen TC, and Lai Y (2013b) Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab Dispos 41:966-974.
49. Varma MV, Scialis RJ, Lin J, Bi YA, Rotter CJ, Goosen TC, and Yang X (2014) Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. AAPS J 16:736-748.
50. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
51. Yoshida K, Maeda K, and Sugiyama Y (2012) Transporter-mediated drug-drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin Pharmacol Ther 91:1053-1064.
52. Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, and Nagar S, et al.; International Transporter Consortium (2013) ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin Pharmacol Ther 94:64-79.